The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy

This review is dedicated to the impact of modern achievements on the definition and diagnostics of castration-resistant prostate cancer (PCa) (CRPC), prognostic factors for its progression, and treatment strategies.It was proven with new sensitive methods of diagnostics that surgical castration (CS)...

Full description

Bibliographic Details
Main Authors:	I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, S. V. Mishugin
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2020-12-01
Series:	Медицинский совет
Subjects:	prostate cancer testosterone castration androgen deprivation leuprorelin acetate
Online Access:	https://www.med-sovet.pro/jour/article/view/5943

Similar Items

How do we define “castration” in men on androgen deprivation therapy?
by: Sarin Itty, et al.
Published: (2020-01-01)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
by: Tunn UW, et al.
Published: (2013-04-01)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
by: Sonja Cabarkapa, et al.
Published: (2018-03-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
by: Hung-Ming Lam, et al.
Published: (2018-05-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Discordance between testosterone measurement methods in castrated prostate cancer patients
by: Mélanie Rouleau, et al.
Published: (2019-02-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
by: Juan Morote, et al.
Published: (2017-10-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
by: Dalsan You, et al.
Published: (2015-03-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
by: Pietro Enea Lazzerini, et al.
Published: (2020-05-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
by: Masaki Shiota, et al.
Published: (2018-12-01)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
by: Rajni Sethi, et al.
Published: (2009-06-01)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
by: Nicoletta Ferrari, et al.
Published: (2017-12-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

The evolution of prostate cancer therapy: targeting the androgen receptor (AR)
by: Jeanny B. Aragon-Ching
Published: (2014-10-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Effective suppression of testosterone: the best castration therapy for hormone-sensitive prostate cancer?
by: A. A. Gritskevich, et al.
Published: (2015-12-01)